A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies

Trial Profile

A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs Cytarabine (Primary)
  • Indications Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Mar 2010 Planned number of patients changed from 36 to 15 as reported by ClinicalTrials.gov.
    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top